DexCom, Inc. $DXCM Shares Sold by Bellevue Group AG

Bellevue Group AG decreased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 19.1% in the 2nd quarter, Holdings Channel reports. The firm owned 860,828 shares of the medical device company’s stock after selling 203,280 shares during the quarter. DexCom comprises about 1.7% of Bellevue Group AG’s investment portfolio, making the stock its 17th biggest holding. Bellevue Group AG’s holdings in DexCom were worth $75,142,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. SWS Partners bought a new position in shares of DexCom during the second quarter valued at approximately $1,661,000. Baader Bank Aktiengesellschaft bought a new stake in shares of DexCom in the 2nd quarter worth approximately $393,000. Jennison Associates LLC boosted its position in DexCom by 9.4% during the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock valued at $1,005,367,000 after purchasing an additional 994,300 shares during the period. Mn Services Vermogensbeheer B.V. grew its stake in DexCom by 4.9% during the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company’s stock worth $12,797,000 after buying an additional 6,800 shares during the last quarter. Finally, Shell Asset Management Co. grew its stake in DexCom by 16.8% during the 2nd quarter. Shell Asset Management Co. now owns 35,812 shares of the medical device company’s stock worth $3,126,000 after buying an additional 5,138 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Down 2.9%

DexCom stock opened at $66.96 on Friday. The stock has a market cap of $26.12 billion, a price-to-earnings ratio of 37.20, a PEG ratio of 1.48 and a beta of 1.51. The company has a current ratio of 1.56, a quick ratio of 1.38 and a debt-to-equity ratio of 0.45. The company’s 50-day moving average price is $64.01 and its two-hundred day moving average price is $74.53. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $93.25.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. The company had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The business’s revenue for the quarter was up 21.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.45 EPS. On average, analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Richard Alexander Collins sold 2,906 shares of the business’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $59.05, for a total value of $171,599.30. Following the sale, the director owned 35,088 shares of the company’s stock, valued at approximately $2,071,946.40. The trade was a 7.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the completion of the sale, the director owned 27,031 shares of the company’s stock, valued at approximately $1,569,690.17. This trade represents a 3.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 7,866 shares of company stock worth $448,177 over the last ninety days. Company insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on DXCM. Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 16th. Sanford C. Bernstein reiterated an “outperform” rating and issued a $84.00 price objective on shares of DexCom in a research report on Monday, November 3rd. JPMorgan Chase & Co. decreased their target price on shares of DexCom from $90.00 to $75.00 and set a “neutral” rating for the company in a research report on Friday, October 31st. The Goldman Sachs Group dropped their price target on shares of DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a research note on Wednesday, October 1st. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of DexCom in a report on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $87.36.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.